Systematic characterization of multi-omics landscape between gut microbial metabolites and GPCRome in Alzheimer’s disease

Qiu, Yunguang; Hou, Yuan; Gohel, Dhruv; Zhou, Yadi; Xu, Jielin; Bykova, Marina; Yang, Yuxin; Leverenz, James B.; Pieper, Andrew A.; Nussinov, Ruth; Caldwell, Jessica Z.K.; Brown, J. Mark; Cheng, Feixiong

doi:10.1016/j.celrep.2024.114128

Cited by 1 publication

(1 citation statement)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both bulk- or single-cell-tailored strategies have been reported for the efficient integration of multi-omics in NDDs drug and target discovery ( Cuperlovic-Culf and Badhwar, 2020 ; Qiu and Cheng, 2024 ). As an example, Qiu et al (2024) recently developed a transcriptomics and proteomics-based systems biology framework to identify AD-related GPCRs and gut metabolites. Further, El Bouhaddani et al (2024) reported a novel probabilistic multi-omics data integration method combining the information of transcriptomics, proteomics, and drug screening data to identify druggable targets involved in synucleinopathies.…”

Section: Practical Aspects For the Design Of Omics-based Drug Screensmentioning

confidence: 99%

Tackling neurodegeneration in vitro with omics: a path towards new targets and drugs

Carraro,

Montgomery,

Klimmt

et al. 2024

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Drug discovery is a generally inefficient and capital-intensive process. For neurodegenerative diseases (NDDs), the development of novel therapeutics is particularly urgent considering the long list of late-stage drug candidate failures. Although our knowledge on the pathogenic mechanisms driving neurodegeneration is growing, additional efforts are required to achieve a better and ultimately complete understanding of the pathophysiological underpinnings of NDDs. Beyond the etiology of NDDs being heterogeneous and multifactorial, this process is further complicated by the fact that current experimental models only partially recapitulate the major phenotypes observed in humans. In such a scenario, multi-omic approaches have the potential to accelerate the identification of new or repurposed drugs against a multitude of the underlying mechanisms driving NDDs. One major advantage for the implementation of multi-omic approaches in the drug discovery process is that these overarching tools are able to disentangle disease states and model perturbations through the comprehensive characterization of distinct molecular layers (i.e., genome, transcriptome, proteome) up to a single-cell resolution. Because of recent advances increasing their affordability and scalability, the use of omics technologies to drive drug discovery is nascent, but rapidly expanding in the neuroscience field. Combined with increasingly advanced in vitro models, which particularly benefited from the introduction of human iPSCs, multi-omics are shaping a new paradigm in drug discovery for NDDs, from disease characterization to therapeutics prediction and experimental screening. In this review, we discuss examples, main advantages and open challenges in the use of multi-omic approaches for the in vitro discovery of targets and therapies against NDDs.

show abstract

Section: Practical Aspects For the Design Of Omics-based Drug Screensmentioning

confidence: 99%

Tackling neurodegeneration in vitro with omics: a path towards new targets and drugs

Carraro,

Montgomery,

Klimmt

et al. 2024

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

Systematic characterization of multi-omics landscape between gut microbial metabolites and GPCRome in Alzheimer’s disease

Cited by 1 publication

References 141 publications

Tackling neurodegeneration in vitro with omics: a path towards new targets and drugs

Tackling neurodegeneration in vitro with omics: a path towards new targets and drugs

Contact Info

Product

Resources

About